The businesses entered into an agreement Nov. 14 to combine, and the resulting company will have an estimated pro-forma enterprise value of $482 million. The transaction is expected to close in early 2022.
Chris Walsh, Accelus CEO and co-founder, will become CEO of the combined company. He has 25 years of experience in the medtech industry with past roles at Stryker and NuVasive.
CHP Merger Corp. is a special purpose acquisition vehicle formed by an affiliate of private equity firm Concord Health Partners.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
